SANTA BARBARA, Calif.--(BUSINESS WIRE)--Feb. 24, 2005--Inamed Corporation (Nasdaq:IMDC):
-- Fourth quarter 2004 sales increased 14% to $103.8 million.
-- Full year 2004 sales increased 16% to $384.4 million.
-- Fourth quarter 2004 diluted GAAP earnings per share were up 18% to $0.52.
-- Full year 2004 diluted GAAP earnings per share were up 16% to $1.75.
-- Full year 2004 diluted Non-GAAP earnings per share were $2.04, excluding a pretax $17.2 million charge for the Ethicon settlement and related litigation expenses.
-- Significant First Quarter 2005 Events:
-- Reached Preliminary Agreement for Reloxin (botulinum toxin type A) Distribution Rights in Select International Markets
-- Silicone Gel-Filled Breast Implant Advisory Panels Scheduled in Canada, United States
Inamed Corporation (Nasdaq:IMDC), a global healthcare company, today announced its financial results for the fourth quarter and the full year ended December 31, 2004.
